login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
PLUS THERAPEUTICS INC (PSTV) Stock News
USA
- NASDAQ:PSTV -
US72941H5090
-
Common Stock
0.5889
USD
-0.01 (-2.22%)
Last: 10/28/2025, 10:14:54 AM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
PSTV Latest News, Press Relases and Analysis
All
Press Releases
7 days ago - By: Plus Therapeutics Inc.
Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch
a month ago - By: Benzinga
- Mentions:
NBY
APDN
GOVX
FATE
...
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 months ago - By: The Motley Fool
Plus Therapeutics Posts Q2 Profit Jump
a month ago - By: Benzinga
- Mentions:
RDHL
CLLS
MRUS
MLTX
...
12 Health Care Stocks Moving In Monday's Pre-Market Session
a month ago - By: Plus Therapeutics Inc.
Plus Therapeutics Announces National Coverage Agreement with UnitedHealthcare Insurance Company for CNSide® Cerebrospinal Fluid Assay for Metastatic CNS Cancer
a month ago - By: Plus Therapeutics Inc.
Plus Therapeutics Announces Additional $1.9 Million Advance Payment from CPRIT
a month ago - By: Plus Therapeutics Inc.
Plus Therapeutics Announces Successful Accreditation and Certification for Its CNSide® Diagnostics Clinical Laboratory
2 months ago - By: Plus Therapeutics Inc.
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
2 months ago - By: Plus Therapeutics Inc.
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
2 months ago - By: Plus Therapeutics Inc.
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
2 months ago - By: Plus Therapeutics Inc.
Plus Therapeutics Reports Stockholders’ Equity in Excess of $2.5 million in Compliance with Nasdaq Equity Requirements
2 months ago - By: Zacks Investment Research
- Mentions:
COO
Plus Therapeutics (PSTV) Reports Q2 Loss, Misses Revenue Estimates
2 months ago - By: Plus Therapeutics Inc.
Plus Therapeutics Reports Second Quarter Financial Results and Recent Business Highlights
3 months ago - By: Plus Therapeutics Inc.
Plus Therapeutics Presents Positive CNSide CSF Assay Platform Results at the 2025 SNO/ASCO CNS Metastases Conference
3 months ago - By: Zacks Investment Research
- Mentions:
XNCR
Xencor (XNCR) Reports Q2 Loss, Tops Revenue Estimates
Please enable JavaScript to continue using this application.